Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells

Huang,Zejian; Zhang,Ning; Li,Wenda; Cao,Jun; Zhang,Lei; Chen,Yajin

doi:10.3892/ol.2016.5466

Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells

Authors:
- Zejian Huang
- Ning Zhang
- Wenda Li
- Jun Cao
- Lei Zhang
- Yajin Chen
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510000, P.R. China
Published online on: December 6, 2016 https://doi.org/10.3892/ol.2016.5466
Pages: 715-721
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer‑associated death. Due to rapid progression and metastasis, the long‑term survival remains poor for most patients. Thus, it is important to discover and develop novel preventive strategies and therapeutic approaches for HCC. Recent data show that chondrolectin (CHODL) is commonly overexpressed in the majority of lung cancers, indicating a possible correlation between CHODL and metastasis of lung cancer cells. Our investigation shows that the expression of CHODL is significantly decreased in HCC clinical samples and in HCC cell lines. Overexpression of CHODL in SMMC7721 cells with a lentiviral vector increased SMMC7721 cell migration and invasion. Our findings establish for the first time an association between human CHODL and HCC metastasis.

View Figures

View References

1	Ferrin G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL and de la Mata M: Biomarkers for hepatocellular carcinoma: Diagnostic and therapeutic utility. Hepat Med. 7:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hong YP, Li ZD, Prasoon P and Zhang Q: Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol. 7:980–992. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gerolami R, Uch R, Jordier F, Chapel S, Bagnis C, Bréchot C and Mannoni P: Gene transfer to hepatocellular carcinoma: Transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 7:1286–1292. 2000. View Article : Google Scholar : PubMed/NCBI
5	Pez F, Lopez A, Kim M, Chapel S, Bagnis C, Bréchot C and Mannoni P: Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bhatia D, Thoppil RJ, Mandal A, Samtani KA, Darvesh AS and Bishayee A: Pomegranate bioactive constituents suppress cell proliferation and induce apoptosis in an experimental model of hepatocellular carcinoma: Role of Wnt/β-catenin signaling pathway. Evid Based Complement Alternat Med. 2013:3718132013. View Article : Google Scholar : PubMed/NCBI
7	Manu KA, Shanmugam MK, Ong TH, Subramaniam A, Siveen KS, Perumal E, Samy RP, Bist P, Lim LH, Kumar AP, et al: Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One. 8:e570152013. View Article : Google Scholar : PubMed/NCBI
8	Weng L, Smits P, Wauters J and Merregaert J: Molecular cloning and characterization of human chondrolectin, a novel type I transmembrane protein homologous to C-type lectins. Genomics. 80:62–70. 2002. View Article : Google Scholar : PubMed/NCBI
9	Weng L, Hubner R, Claessens A, Smits P, Wauters J, Tylzanowski P, Van Marck E and Merregaert J: Isolation and characterization of chondrolectin (Chodl), a novel C-type lectin predominantly expressed in muscle cells. Gene. 308:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
10	Weng L, Van Bockstaele DR, Wauters J, Van Marck E, Plum J, Berneman ZN and Merregaert J: A novel alternative spliced chondrolectin isoform lacking the transmembrane domain is expressed during T cell maturation. J Biol Chem. 278:19164–19170. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sleigh JN, Barreiro-Iglesias A, Oliver PL, Biba A, Becker T, Davies KE, Becker CG and Talbot K: Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum Mol Genet. 23:855–869. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhong Z, Ohnmacht J, Reimer MM, Bach I, Becker T and Becker CG: Chondrolectin mediates growth cone interactions of motor axons with an intermediate target. J Neurosci. 32:4426–4439. 2012. View Article : Google Scholar : PubMed/NCBI
13	Claessens A, Van de Vijver K, Van Bockstaele DR, Wauters J, Berneman ZN, Van Marck E and Merregaert J: Expression and localization of CHODLDeltaE/CHODLfDeltaE, the soluble isoform of chondrolectin. Cell Biol Int. 31:1323–1330. 2007. View Article : Google Scholar : PubMed/NCBI
14	Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y: Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 17:7712–7722. 2011. View Article : Google Scholar : PubMed/NCBI
15	Dang H, Steinway SN, Ding W and Rountree CB: Induction of tumor initiation is dependent on CD44s in c-Met+ hepatocellular carcinoma. Bmc Cancer. 15:1612015. View Article : Google Scholar : PubMed/NCBI
16	Deng L, Li G, Xi L, Yin A, Gao Y, You W, Wang X and Sun B: Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol. 9:732009. View Article : Google Scholar : PubMed/NCBI
17	Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, et al: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011. View Article : Google Scholar : PubMed/NCBI
18	Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A and Grigioni WF: Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 35:332–338. 2003. View Article : Google Scholar : PubMed/NCBI
19	Forner A, Hessheimer AJ, Real M Isabel and Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
20	Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C and Wong J: Hepatectomy for hepatocellular carcinoma: Toward zero hospital deaths. Ann Surg. 229:322–330. 1999. View Article : Google Scholar : PubMed/NCBI
21	Chang LJ, Urlacher V, Iwakuma T, Cui Y and Zucali J: Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6:715–728. 1999. View Article : Google Scholar : PubMed/NCBI
22	Liu Y, Butterfield LH, Fu X, Song Z, Zhang X, Lu C, Ding G and Wu M: Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. Int J Oncol. 39:245–253. 2011.PubMed/NCBI
23	Wang Q, Liu QY, Liu ZS, Qian Q, Sun Q and Pan DY: Lentivirus mediated shRNA interference targeting MAT2B induces growth-inhibition and apoptosis in hepatocelluar carcinoma. World J Gastroenterol. 14:4633–4642. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kafri T, Blomer U, Peterson DA, Gage FH and Verma IM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 17:314–317. 1997. View Article : Google Scholar : PubMed/NCBI